Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial-Reference-Cited by-同舟云学术

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial

Published:2018-12 Issue:10165 Volume:392 Page:2718-2727
ISSN:0140-6736
Container-title:The Lancet
language:en
Short-container-title:The Lancet

Author:

Reisinger Emil C,Tschismarov Roland,Beubler Eckhard,Wiedermann Ursula,Firbas Christa,Loebermann Micha,Pfeiffer Andrea,Muellner Matthias,Tauber Erich,Ramsauer Katrin

Publisher

Elsevier BV

Subject

General Medicine

Reference26 articles.

1. Global risk mapping for major diseases transmitted by Aedes aegypti and Aedes albopictus;Leta;Int J Infect Dis,2018

2. Global expansion of chikungunya virus: mapping the 64-year history;Wahid;Int J Infect Dis,2017

3. High level of vector competence of Aedes aegypti and Aedes albopictus from ten American countries as a crucial factor in the spread of chikungunya virus;Vega-Rua;J Virol,2014

4. High efficiency of temperate Aedes albopictus to transmit chikungunya and dengue viruses in the southeast of France;Vega-Rua;PLoS One,2013

Cited by 124 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity and Safety of Chikungunya Vaccines: A Systematic Review and Meta-Analysis;Vaccines;2024-08-27

2. Chikungunya virus vaccine: a decade of progress solving epidemiological dilemma, emerging concepts, and immunological interventions;Frontiers in Microbiology;2024-07-22

3. Advancements in chikungunya virus management: FDA approval of ixchiq vaccine and global perspectives;Health Science Reports;2024-06

4. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: protection of African green monkeys from COVID-19 disease;Journal of Virology;2024-05-14

5. A measles-vectored vaccine candidate expressing prefusion-stabilized SARS-CoV-2 spike protein brought to phase I/II clinical trials: candidate selection in a preclinical murine model;Journal of Virology;2024-05-14